Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009252
Filing Date
2025-05-08
Accepted
2025-05-08 16:06:35
Documents
56
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 585473
2 EX-31.1 ex31-1.htm EX-31.1 9261
3 EX-31.2 ex31-2.htm EX-31.2 9158
4 EX-32.1 ex32-1.htm EX-32.1 8751
5 form10-q_001.jpg GRAPHIC 212074
  Complete submission text file 0001641172-25-009252.txt   4163470

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pcsa-20250331.xsd EX-101.SCH 33024
7 XBRL CALCULATION FILE pcsa-20250331_cal.xml EX-101.CAL 39881
8 XBRL DEFINITION FILE pcsa-20250331_def.xml EX-101.DEF 139916
9 XBRL LABEL FILE pcsa-20250331_lab.xml EX-101.LAB 313678
10 XBRL PRESENTATION FILE pcsa-20250331_pre.xml EX-101.PRE 249934
58 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 363630
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Filer) CIK: 0001533743 (see all company filings)

EIN.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39531 | Film No.: 25925993
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)